Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T11280 |
FGFR4-IN-4
|
FGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
FGFR4-IN-4 is a FGFR4 inhibitor with anti-tumor activity. | |||
TQ0256 |
FGFR4-IN-1
|
FGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
FGFR4-IN-1 是一种 FGFR4 抑制剂 (IC50:0.7 nM)。 | |||
T37425 |
FGFR4-IN-5
FGFR4-IN-5 |
||
FGFR4-IN-5, a covalent FGFR4 inhibitor, demonstrates potency and selectivity with an IC50 value of 6.5 nM. Exhibiting significant in vivo anti-tumor activity, it is applicable for research in hepatocellular carcinoma [1]. | |||
T4235 |
Roblitinib
FGF-401 |
FGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Roblitinib (FGF-401) 是一种口服有效的,高选择性的FGFR4抑制剂(IC50:1.9 nM),具有抗癌作用。 | |||
T79880 |
FGFR4-IN-16
|
FGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
FGFR4-IN-16 (CY-15-2)为FGFR-4选择性共价抑制剂,适用于癌症研究领域。 | |||
T83911 |
CYY292
|
||
CYY292是一种针对PDGFRα、PDGFRβ、FGFR1、-2和-3的抑制剂(IC50分别为5.35、4.6、28、28和78 nM)。该化合物对这些激酶的选择性高于FGFR4(IC50 > 1,000 nM),但也能抑制c-Kit、VEGFR2、VEGFR1和胰岛素样生长因子1受体(IGF-1R;IC50分别为67、33、36和75 nM),以及EGFR、布鲁顿酪氨酸激酶(BTK)、细胞周期依赖性激酶4(Cdk4)/cyclin D3和MET(IC50分别为128、198、214和396 nM)。CYY292抑制MG-63、U2OS、MNNG/HOS和Saos-2骨肉瘤细胞的增殖(IC50分别为0.84、0.76、1.36和0.72 µM)。在0.3和0.5 µM的浓度下,它抑制U87MG和LN-229胶质母细胞瘤细胞的迁移和侵袭。CYY292(30 mg/kg)在U87MG原位小鼠异种移植模型中降低肿瘤体积并增加生存率。 |